ORGENESIS INC (ORGS)
US68619K2042 - Common Stock
Overall ORGS gets a fundamental rating of 1 out of 10. We evaluated ORGS against 587 industry peers in the Biotechnology industry. ORGS has a bad profitability rating. Also its financial health evaluation is rather negative. ORGS has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ORGS had negative earnings in the past year.
ORGS had a negative operating cash flow in the past year.
ORGS had negative earnings in 4 of the past 5 years.
In the past 5 years ORGS always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -189.62%, ORGS is not doing good in the industry: 89.23% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -189.62% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ORGS has a better Gross Margin (56.19%) than 80.68% of its industry peers.
ORGS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ORGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ORGS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ORGS has been increased compared to 5 years ago.
ORGS has a worse debt/assets ratio than last year.
2.2 Solvency
ORGS has an Altman-Z score of -19.92. This is a bad value and indicates that ORGS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -19.92, ORGS is doing worse than 86.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.92 |
ROIC/WACCN/A
WACC5.92%
2.3 Liquidity
ORGS has a Current Ratio of 0.25. This is a bad value and indicates that ORGS is not financially healthy enough and could expect problems in meeting its short term obligations.
ORGS has a Current ratio of 0.25. This is amonst the worse of the industry: ORGS underperforms 98.12% of its industry peers.
ORGS has a Quick Ratio of 0.25. This is a bad value and indicates that ORGS is not financially healthy enough and could expect problems in meeting its short term obligations.
ORGS has a Quick ratio of 0.25. This is amonst the worse of the industry: ORGS underperforms 97.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.25 | ||
| Quick Ratio | 0.25 |
3. Growth
3.1 Past
The earnings per share for ORGS have decreased strongly by -62.86% in the last year.
The Revenue for ORGS has decreased by -60.31% in the past year. This is quite bad
Measured over the past years, ORGS shows a very negative growth in Revenue. The Revenue has been decreasing by -50.95% on average per year.
EPS 1Y (TTM)-62.86%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-38.03%
Revenue 1Y (TTM)-60.31%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Revenue growth Q2Q-98.79%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ORGS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 0.84, which indicates a rather cheap valuation of ORGS.
Based on the Price/Forward Earnings ratio, ORGS is valued cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ORGS to the average of the S&P500 Index (20.58), we can say ORGS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0.84 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ORGS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORGENESIS INC
NASDAQ:ORGS (5/6/2024, 7:19:25 PM)
After market: 0.5432 +0.02 (+4.46%)0.52
-0.01 (-1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap17.86M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0.84 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -189.62% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.19% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.25 | ||
| Quick Ratio | 0.25 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-62.86%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y190.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-60.31%
Revenue growth 3Y-58.93%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y